Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Gala Health vs Onyx Weight Loss

Gala Health
Graded #17

Higher grade

vs+24.10000000000001
Onyx Weight Loss
Graded #359

Lower grade

The verdict

Gala Health takes it — 82.9/100 to 58.8/100.

Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A compounded tirzepatide and semaglutide program for women that reaches all 50 states and keeps a brand-name Ozempic path open — but its $179 and $149 headline rates are yearly-subscription prices, not monthly ones.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGala Health +41
84
43
Dose & formulationGala Health +19
83
64
Clinical oversightGala Health +10
85
75
Labs & monitoringGala Health +20
83
63
FulfillmentGala Health +35
88
53
Contract termsGala Health +11
66
55
Gala Health · left barOnyx Weight Loss · right bar

The numbers

MetricGala HealthOnyx Weight Loss
WeighScore82.9/10058.8/100
GradeB−C
Scorecard rank#17#359
SemaglutideNot disclosed$228/mo (starting dose, compounded)
Tirzepatide$179/mo (yearly subscription)$280/mo (starting dose, compounded)
CoverageAll 50 states8 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Gala Health

Graded #17 · B−

Strengths

  • Low compounded entry if you prepay the year — $179/mo tirzepatide and $149/mo microdose on the yearly subscription, $199/mo on a 3-month plan
  • Prices are published openly rather than quiz-gated, with all doses included at the one rate
  • All 50 states and LegitScript-verified, with a brand-name Ozempic path kept open ($1,299)
  • HRT and menopause care available alongside GLP-1

Where it loses points

  • No month-to-month price is published anywhere — the $179 tirzepatide and $149 microdose rates are both yearly subscriptions, and the shortest term Gala names is a 3-month plan at $199/mo
  • Compounded formulations are not FDA-approved
  • Brand-name Ozempic is priced steeply at $1,299
  • No oral or sublingual route offered yet — injection only
  • Newer operator (Gala GLP-1 by AI Coaching Inc) with no named clinicians and no named dispensing pharmacy
Onyx Weight Loss

Graded #359 · C

Strengths

  • Competitive entry pricing: semaglutide from $228/mo and tirzepatide from $280/mo with medication + supplies included
  • Nurse-practitioner-led care: founder Tasha Vangile FNP-C (20+ years) and Stephanie Robison APRN-CNP (27 years experience)
  • Low-cost $99/mo GLP-1 microdosing option for patients who prefer a gradual titration start
  • Strive Pharmacy partnership implies compounded 503A-quality supply chain from a known pharmacy
  • Multi-modal clinic: GLP-1 + peptides + HRT + nutrition coaching available under one provider team

Where it loses points

  • Only 8 states (NC, CO, ME, VT, VA, IA, NH, PA) — excludes the majority of the US
  • No LegitScript certification; credentialing evidence limited to local 2025 Best of Iredell award
  • Specific drug names (semaglutide/tirzepatide) never stated on website; compounded status inferred, not disclosed
  • Labs not included or mentioned; no baseline bloodwork protocol published
  • Pricing shown as 'Starting at' with no dose-escalation tier pricing disclosed publicly

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard